The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Molecular targeting of the oncogene eIF4E in acute myeloid leukemia (AML): a proof-of-principle clinical trial with ribavirin
Open accessAbstract
The eukaryotic translation initiation factor eIF4E is elevated in 30% of malignancies including M4/M5 subtypes of acute myeloid leukemia (AML). The oncogenic potential of eIF4E arises from its ability to bind the 7-methyl guanosine (m7G) cap on mRNAs, thereby selectively enhancing eIF4E-dependent nuclear mRNA export and translation. We tested the clinical efficacy of targeting eIF4E in M4/M5 AML patients with a physical mimic of the m7G cap, ribavirin. Among 11 evaluable patients there were 1 complete remission (CR), 2 partial remissions (PRs), 2 blast responses (BRs), 4 stable diseases (SDs), and 2 progressive diseases (PDs). Ribavirin-induced relocalization of nuclear eIF4E to the cytoplasm and reduction of eIF4E levels were associated with clinical response. Lack of response or relapse coincided with continued or renewed nuclear localization of eIF4E. This first clinical study to target eIF4E in human malignancy demonstrates clinical activity and associated molecular responses in leukemic blasts. This trial is registered at ClinicalTrials.gov (NCT00559091).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cheson, B. D., Bennett, J. M., Kopecky, K. J., Büchner, T., Willman, C. L., Estey, E. H., Schiffer, C. A., Doehner, H., Tallman, M. S., Lister, T. A., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.04.036 · Cited by 2,654
Creutzig, U., & Kaspers, G. J. L. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.99.116 · Cited by 2,137
Does the ribosome translate cancer?
Ruggero, D., & Pandolfi, P. P. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1015 · Cited by 928
Graff, J. R., Konicek, B. W., Vincent, T. M., Lynch, R. L., Monteith, D., Weir, S. N., Schwier, P., Capen, A., Goode, R. L., Dowless, M. S., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci32044 · Cited by 380
Kentsis, A., Topisirovic, I., Culjkovic, B., Shao, L., & Borden, K. L. B. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0406927102 · Cited by 305
Self-citationGraff, J. R., & Zimmer, S. G. (2003) · Clinical & Experimental Metastasis · doi:10.1023/a:1022943419011 · Cited by 215
Topisirovic, I., Guzman, M. L., McConnell, M. J., Licht, J. D., Culjkovic, B., Neering, S. J., Jordan, C. T., & Borden, K. L. B. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.24.8992-9002.2003 · Cited by 206
Self-citationPML RING suppresses oncogenic transformation by reducing the affinity of eIF4E for mRNA
Cohen, N. (2001) · The EMBO Journal · doi:10.1093/emboj/20.16.4547 · Cited by 188
Čuljković, B., Topisirović, I., & Borden, K. L. B. (2007) · Cell Cycle · doi:10.4161/cc.6.1.3688 · Cited by 181
Self-citationTopisirovic, I. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg069 · Cited by 171
Cited by
Drug repurposing: progress, challenges and recommendations
Pushpakom, S., Iorio, F., Eyers, P. A., Escott, K. J., Hopper, S., Wells, A., Doig, A., Guilliams, T., Latimer, J., McNamee, C., et al. (2019) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.168 · Cited by 4,718
Goodall, G. J., & Wickramasinghe, V. O. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-020-00306-0 · Cited by 1,066
Targeting the translation machinery in cancer
Bhat, M., Robichaud, N., Hulea, L., Sonenberg, N., Pelletier, J., & Topisirovic, I. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4505 · Cited by 799
Drosophila neuroblasts: a model for stem cell biology
Homem, C. C. F., & Knoblich, J. A. (2012) · Development · doi:10.1242/dev.080515 · Cited by 476
Cap and cap‐binding proteins in the control of gene expression
Topisirovic, I., Svitkin, Y. V., Sonenberg, N., & Shatkin, A. J. (2011) · WIREs RNA · doi:10.1002/wrna.52 · Cited by 401
Metadata
- Authors
- Assouline, S., Culjkovic, B., Cocolakis, E., Rousseau, C., Beslu, N., Amri, A., Caplan, S., Leber, B., Roy, D.-C., Miller, W. H., & Borden, K. L. B.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2009-07-09
- Volume
- 114
- Issue
- 2
- Pages
- 257-260
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2112519486
- Cited by
- 314
- References
- 18
- FWCI
- 12.08
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Molecular targeting of the oncogene eIF4E in acute myeloid leukemia (AML): a proof-of-principle clinical trial with ribavirin. https://app.cochat.ai/papers/10.1182/blood-2009-02-205153
- The paper
- Assouline, S., Culjkovic, B., Cocolakis, E., Rousseau, C., Beslu, N., Amri, A., Caplan, S., Leber, B., Roy, D.-C., Miller, W. H., & Borden, K. L. B. (2009). Molecular targeting of the oncogene eIF4E in acute myeloid leukemia (AML): a proof-of-principle clinical trial with ribavirin. Blood. https://doi.org/10.1182/blood-2009-02-205153
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.